Prominent publications by MICHAEL SHECHTER
BACKGROUND: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4-1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore ...
| Known for Odyssey Outcomes | Coronary Syndrome | Patients Alirocumab | Controlled Trial | Primary Endpoint |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
[ PUBLICATION ]
BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.
OBJECTIVES: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute ...
| Known for Cardiovascular Outcomes | Acute Coronary | Statin Treatment | Mace Ldlc | 9 Inhibition |
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
[ PUBLICATION ]
OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor.
RESEARCH DESIGN AND METHODS: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients ...
| Known for 2 Diabetes | Levels Lipoproteina | Acute Coronary Syndrome | Proprotein Convertase | Therapies Reduce |
| Known for Arterial Hypertension | 2018 Esc | Esh Guidelines |
MICHAEL SHECHTER: Influence Statistics
| Concept | World rank |
|---|---|
| elderly coronary | #90 |
| obesity societies | #96 |
Key People For Odyssey Outcomes
MICHAEL SHECHTER:Expert Impact
Concepts for whichMICHAEL SHECHTERhas direct influence:Odyssey outcomes, Alirocumab treatment, Placebo patients, Patients alirocumab, Incident type, Patients prediabetes, 2 diabetes, Type 2.
MICHAEL SHECHTER:KOL impact
Concepts related to the work of other authors for whichfor which MICHAEL SHECHTER has influence:Blood pressure, Cardiovascular disease, Arterial hypertension, Hypertensive patients, Heart failure, Diabetes mellitus, Renal denervation.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |